Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
tHU2QeK6zAKwGjZW
